Cargando…

129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure

BACKGROUND: Clostridioides difficile can colonize or cause symptomatic disease from mild diarrhea to severe colonic inflammation requiring surgical intervention. Multiple C. difficile diagnostics are available and national guidelines recommend standalone or combination testing methods. Testing has m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Nicholas, Wilson, Sydney, Aragon, Laura, Boyd, Sarah E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678495/
http://dx.doi.org/10.1093/ofid/ofad500.202
_version_ 1785150375308820480
author Bennett, Nicholas
Wilson, Sydney
Aragon, Laura
Boyd, Sarah E
author_facet Bennett, Nicholas
Wilson, Sydney
Aragon, Laura
Boyd, Sarah E
author_sort Bennett, Nicholas
collection PubMed
description BACKGROUND: Clostridioides difficile can colonize or cause symptomatic disease from mild diarrhea to severe colonic inflammation requiring surgical intervention. Multiple C. difficile diagnostics are available and national guidelines recommend standalone or combination testing methods. Testing has mostly shifted to polymerase chain reaction (PCR)-based, which has shown up to a 50% increase in reporting of C. difficile infection (CDI). A two-step testing method has also been used to discern colonization versus active infection. The National Healthcare Safety Network has proposed changes to CDI reporting to include results and treatment, emphasizing the importance of diagnostic and antimicrobial stewardship. METHODS: In 2021 Saint Luke’s Health System moved from C. difficile PCR standalone to two-step testing with PCR and enzyme immunoassay (EIA) toxin test. If PCR is positive, an EIA is run. Both results are reported including interpretation guidance. A retrospective cohort study was conducted to evaluate if two-step testing impacts antibiotic prescribing rates for C. difficile. The pre-implementation group included PCR-only and post- implementation was split into PCR +/ EIA - and PCR +/ EIA + groups. RESULTS: Treatment rates for C. difficile did not significantly change after implementation of two-step testing (100% pre- vs 92% PCR +/ EIA - and 97% PCR +/ EIA +, p = 0.093). For PCR +/ EIA - results, treatment initiation more often occurred prior to results being available compared to the post-implementation PCR +/ EIA + group and pre-implementation group (30.3% PCR +/ EIA - vs 19.6% PCR +/ EIA + and 7.8% pre-implementation, (p = 0.028)). C. difficile antibiotic prescribing rates at discharge were no different between groups as the highest rates of treatment continuation were seen in the PCR +/ EIA - group (79.4% PCR +/ EIA - 72.5% pre-implementation vs 71.7% PCR+/ EIA +, p = 0.706). CONCLUSION: Despite PCR +/ EIA - results, clinicians tended to treat patients irrespective of PCR-only or two-step results. The impact of two-step C. difficile testing on treatment rates was limited and prescribing rates did not significantly change. The findings of this study warrant investigation into alternative solutions to promote aligned diagnostic and antimicrobial stewardship. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678495
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106784952023-11-27 129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure Bennett, Nicholas Wilson, Sydney Aragon, Laura Boyd, Sarah E Open Forum Infect Dis Abstract BACKGROUND: Clostridioides difficile can colonize or cause symptomatic disease from mild diarrhea to severe colonic inflammation requiring surgical intervention. Multiple C. difficile diagnostics are available and national guidelines recommend standalone or combination testing methods. Testing has mostly shifted to polymerase chain reaction (PCR)-based, which has shown up to a 50% increase in reporting of C. difficile infection (CDI). A two-step testing method has also been used to discern colonization versus active infection. The National Healthcare Safety Network has proposed changes to CDI reporting to include results and treatment, emphasizing the importance of diagnostic and antimicrobial stewardship. METHODS: In 2021 Saint Luke’s Health System moved from C. difficile PCR standalone to two-step testing with PCR and enzyme immunoassay (EIA) toxin test. If PCR is positive, an EIA is run. Both results are reported including interpretation guidance. A retrospective cohort study was conducted to evaluate if two-step testing impacts antibiotic prescribing rates for C. difficile. The pre-implementation group included PCR-only and post- implementation was split into PCR +/ EIA - and PCR +/ EIA + groups. RESULTS: Treatment rates for C. difficile did not significantly change after implementation of two-step testing (100% pre- vs 92% PCR +/ EIA - and 97% PCR +/ EIA +, p = 0.093). For PCR +/ EIA - results, treatment initiation more often occurred prior to results being available compared to the post-implementation PCR +/ EIA + group and pre-implementation group (30.3% PCR +/ EIA - vs 19.6% PCR +/ EIA + and 7.8% pre-implementation, (p = 0.028)). C. difficile antibiotic prescribing rates at discharge were no different between groups as the highest rates of treatment continuation were seen in the PCR +/ EIA - group (79.4% PCR +/ EIA - 72.5% pre-implementation vs 71.7% PCR+/ EIA +, p = 0.706). CONCLUSION: Despite PCR +/ EIA - results, clinicians tended to treat patients irrespective of PCR-only or two-step results. The impact of two-step C. difficile testing on treatment rates was limited and prescribing rates did not significantly change. The findings of this study warrant investigation into alternative solutions to promote aligned diagnostic and antimicrobial stewardship. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678495/ http://dx.doi.org/10.1093/ofid/ofad500.202 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Bennett, Nicholas
Wilson, Sydney
Aragon, Laura
Boyd, Sarah E
129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure
title 129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure
title_full 129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure
title_fullStr 129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure
title_full_unstemmed 129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure
title_short 129. Evaluation of Two-Step Clostridioides difficile Testing on Treatment Exposure
title_sort 129. evaluation of two-step clostridioides difficile testing on treatment exposure
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678495/
http://dx.doi.org/10.1093/ofid/ofad500.202
work_keys_str_mv AT bennettnicholas 129evaluationoftwostepclostridioidesdifficiletestingontreatmentexposure
AT wilsonsydney 129evaluationoftwostepclostridioidesdifficiletestingontreatmentexposure
AT aragonlaura 129evaluationoftwostepclostridioidesdifficiletestingontreatmentexposure
AT boydsarahe 129evaluationoftwostepclostridioidesdifficiletestingontreatmentexposure